TABLE 1.
TRANSDUCED PBL SPECIFICITY
| Stimulators |
||||||
|---|---|---|---|---|---|---|
| Responder cells | Vector | T2 alone | T2+FLU | T2+gp100 | T2+MART | |
| pg/ml IFN-γ | ||||||
| PBL | MSGIN | 464 | 001 | 10,856 | 409 | |
| APB 9 | gp100 | 532 | 659 | 44,065 | 591 | |
| AIB 18 | MART | 209 | 178 | 403 | 48,375 | |
| BPA 34 | MART | 515 | 509 | 687 | 52,706 | |
| BIA 71 | MART | 628 | 519 | 15,457 | 75,546 | |
| PBL-MART | NONE | 0 | 0 | 428 | 49,376 | |
| pg/ml GM-CSF | ||||||
| PBL | ||||||
| PBL | MSGIN | 437 | 573 | 722 | 786 | |
| APB 9 | gp100 | 498 | 901 | 1200 | 715 | |
| AIB 18 | MART | 567 | 702 | 738 | 5,100 | |
| PBL-MART | NONE | 1 | 3 | 45 | 2,200 | |
| pg/ml IL-2 | ||||||
| PBL | MSGIN | 0 | 0 | 0 | 0 | |
| APB9 | gp100 | 0 | 0 | 0 | 0 | |
| AIB 18 | MART | 0 | 0 | 0 | 72 | |
| BPA 34 | MART | 0 | 0 | 0 | 78 | |
| BIA 71 | MART | 0 | 18 | 0 | 189 | |
| PBL-MART | NONE | 0 | 0 | 25 | 122 | |
| pg/ml TNF-α | ||||||
| PBL | NONE | 0 | 0 | 0 | 9 | |
| PBL | MSGIN | 0 | 0 | 0 | 0 | |
| APB9 | gp100 | 0 | 0 | 287 | 0 | |
| AIB 18 | MART | 0 | 0 | 0 | 2,552 | |
| AIB 54 | MART | 0 | 0 | 0 | 1,941 | |
| Stimulators (pg/ml IFN-α) | ||||||
| T2+MART | 100 ng/ml | 10 ng/ml | 1 ng/ml | 0.1 ng/ml | 0.01 ng/ml | T2 alone |
| Responder | ||||||
| AIB 18 | 115 | 746 | 570 | 73 | 0 | 0 |
| JB2F4 | 800 | 511 | 380 | 48 | 0 | 0 |
Cytokine production of transduced peripheral blood lymphocytes (PBL) in coculture with peptide pulsed T2 cells. MSGIN is a control vector, which contains green fluorescent protein. APB9 is a retroviral vector encoding the anti-gp100 TCR. AIB 18, BPA 34, BIA 71, and AIB 54 are anti-MART-1 TCR containing retroviruses. PBL-MART is a PBL that was stimulated in vitro with MART-1 peptide and JB2F4 is a MART-1-specific cytotoxic T lymphocyte; both used as positive controls.
IFN-γ, interferon-γ; TNF-α, tumor necrosis factor-α; IL. Interleukin-2; GM-CSF, granulocyte macrophagecolony stimulating factor.